Photocure ASA (0IMT.L) LSE
59.70
+4(+7.18%)
Currency In NOK
- General
- Statistics
- Historical Data
- Profile
- Financials
59.70
+4(+7.18%)
Currency In NOK
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
99
First IPO Date
January 14, 2011
| Name | Title | Pay | Year Born |
| Daniel Schneider | President & Chief Executive Officer | 0 | N/A |
| Anja Gossens-von der Heidt | Head of Global Human Resources | 0 | N/A |
| Anders Neijber | Chief Medical Officer of Global Medical Affairs, Clinical Development and R&D | 0 | N/A |
| David Moskowitz | Head of Investor Relations | 0 | N/A |
| Erik Dahl | Chief Financial Officer | 0 | 1957 |
| Tolv Hillestad | Group Controller | 0 | N/A |
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, Italy, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.